Jyong Biotech (NASDAQ:MENS) Trading Up 8.3% – Should You Buy?

Shares of Jyong Biotech Ltd. (NASDAQ:MENS) traded up 8.3% during trading on Thursday . The company traded as high as $2.38 and last traded at $2.22. Approximately 207,455 shares traded hands during mid-day trading, an increase of 33% from the average daily volume of 156,337 shares. The stock had previously closed at $2.05.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Jyong Biotech in a research report on Friday, May 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Jyong Biotech currently has a consensus rating of “Sell”.

Jyong Biotech Stock Performance

The stock has a 50 day simple moving average of $2.00 and a 200-day simple moving average of $2.63.

Jyong Biotech (NASDAQ:MENS) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.02) earnings per share for the quarter.

Institutional Investors Weigh In On Jyong Biotech

A number of hedge funds have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. bought a new stake in shares of Jyong Biotech during the 4th quarter valued at $49,000. Man Group plc bought a new position in Jyong Biotech in the 4th quarter worth $56,000. BNP Paribas Financial Markets purchased a new position in Jyong Biotech during the third quarter valued at $67,000. Millennium Management LLC grew its holdings in Jyong Biotech by 209.4% during the fourth quarter. Millennium Management LLC now owns 40,258 shares of the company’s stock valued at $159,000 after purchasing an additional 27,245 shares during the period. Finally, Geode Capital Management LLC increased its position in Jyong Biotech by 19.6% in the fourth quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock worth $254,000 after buying an additional 10,538 shares in the last quarter.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.